Promyelocytic leukemia, a unique model to design treatments targeting oncogenes;La leucémie aiguë promyélocytaire : Un paradigme des traitements ciblés sur l'oncogène?

Medecine/Sciences

Volumn 17, Issue 1, 2001, Pages 14-22

  Lallemand Breitenbach, V ^a   Zhu, J ^a   De The H ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; CELL NUCLEUS RECEPTOR; HYBRID PROTEIN; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER REGRESSION; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; GENE TARGETING; GENE THERAPY; GENE TRANSLOCATION; LEUKEMIA CELL; LEUKEMOGENESIS; MOUSE; NONHUMAN; RECEPTOR AFFINITY; RECEPTOR GENE; REVIEW; TRANSGENIC MOUSE;

ANIMALIA; MUS MUSCULUS;

EID: 0035139906     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.4267/10608/1783     Document Type: Review

References (52)

1. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia
2. PML, a growth suppressor disrupted in acute promyelocytic leukemia
3. The PML growth-suppressor has an altered expression in human oncogenesis
4. PML is essential for multiple apoptotic pathways
5. PML induces a caspase-independent cell death process
6. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor a locus due to a variant t(11,17) translocation in acute promyelocytic leukemia
7. The t(5-17) variant of acute promyelocytic leukemia expresses a nucleophosmin retinoic acid receptor fusion
8. Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia
9. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia
10. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RARalpha under control of cathepsin G regulatory sequences
11. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice
12. A PML RAR alpha transgene initiates murine acute promyelocytic leukemia
13. The acute promyelocytic leukemia PML-RAR alpha protein induces hepatic preneoplastic and neoplastic lesions in transgenic mice
14. A bcr-3 isoform of RARα/PML potentialtes the development of PML/RARα-driven acute promyelocytic leukemia
15. Overexpression of wild-type retinoic acid receptor alpha (RAR alpha) recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RAR alpha-fusion genes
16. Vitamin A deficiency in mice causes a systemic expansion of myeloid cells
17. A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocytic stage
18. Impaired granulocytic differentiation in vitro in hematopoietic cells lacking retinoic acid receptors alpha1 and gamma
19. A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest
20. Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor
21. The acute promyelocytic leukemia specific PML/RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells
22. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha fusion proteins on retinoic acid signalling
23. Acute promyelocytic leukemia: From treatment to genetics and back
24. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia
25. Role of the histone deacetylase complex in acute promyelocytic leukaemia
26. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers
27. The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells
28. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein
29. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RAR alpha) and oncogenic RAR alpha fusion proteins
30. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant tt(11;17)(q23;q21) APL patient
31. Leukemia-associated retinoic acid receptor α fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies
32. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
33. RAR-independent RXR signaling induces t(15;17) leukemia cell maturation
34. PML regulates p53 acetylation and premature senescence induces by oncogenic Ras
35. PML is induced by oncogenic ras and promotes premature senescence
36. A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RAR alpha and T18 oncoproteins
37. Role of PML in cell growth and the retinoic acid pathway
38. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein
39. The t(15,17) translocation alters a nuclear body in a RA-reversible fashion
40. PML is critical for ND10 formation and recruits the PML-interacting protein Daxx to this nuclear structure when modified by SUMO-1
41. Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling
42. Human Daxx regulates Fas-induced apoptosis from nuclear PML oncogenic domains (PODs)
43. Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis
44. 3 exerts dose- dependent dual effects on APL cells
45. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
46. Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia
47. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus
48. Pic-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia
49. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner
50. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia. Possible role of the proteasome pathway
51. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells
52. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia